What is pertuzumab used to treat?
Pertuzumab (Perjeta®) and trastuzumab are only used to treat breast cancers that have too much of a protein (receptor) called HER2 on the surface of their cells. This is called HER2-positive breast cancer.
Who owns PERJETA?
Genentech: Perjeta® (pertuzumab) – Information for Patients.
What is the difference between trastuzumab and pertuzumab?
Pertuzumab is a fully humanized monoclonal antibody which binds to domain II of HER2, essential for dimerization [27, 59], while trastuzumab binds to domain IV. Pertuzumab efficiently inhibits ligand-induced HER2/HER3 dimerization, whereas trastuzumab has only a minor effect in the presence of a ligand.
What is the brand name for pertuzumab?
Pertuzumab is a targeted cancer drug and is also known by its brand name Perjeta. It also used to be called Omnitarg.
How long can you take pertuzumab?
Before surgery, pertuzumab is given for three to six cycles alongside trastuzumab and chemotherapy. After surgery, it’s given alongside trastuzumab and chemotherapy for around one year. Some people have pertuzumab before and after surgery. Up to 18 cycles can be given in total.
Does pertuzumab cause hair loss?
Pertuzumab and trastuzumab don’t usually cause people to lose their hair. Any hair loss caused by chemotherapy should be temporary and in most cases your hair will begin to grow back once your chemotherapy treatment has ended.
Is pertuzumab an immunotherapy?
Passive immunotherapy has provided several successful treatments for breast cancer. The current mainstay of passive immunotherapy includes trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).
Is pertuzumab a cardiotoxic?
The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well established. However, the cardiotoxic effect of pertuzumab, another HER2-directed therapy, is less well documented.
Is pertuzumab a chemo drug?
Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”.
What should I monitor with pertuzumab?
Monitoring and Testing: Lab work to check blood counts and liver/kidney functions will be checked regularly by your health care professional while you are taking Pertuzumab, to monitor side effects and check your response to therapy.
Is pertuzumab a chemotherapy?
Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”. (For more detail, see “How Pertuzumab Works” below).
What happened to Genentech pertuzumab?
In 2005 Genentech presented poor results of Phase II trials of pertuzumab as a single agent in prostate, breast, and ovarian cancers, and said that it intended to continue developing it in combination with other drugs for ovarian cancer. In 2007 Genentech dropped the trade name Omnitarg.
When was pertuzumab first approved?
It was discovered and developed by Genentech, a subsidiary of Roche, and was first approved in 2012. Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer.
Can it be given as an infusion instead of pertuzumab?
It can be given in less time than pertuzumab or trastuzumab, which are given as infusions. For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for Pertuzumab and Trastuzumab.
What is pertuzumab made of?
Chemistry and manufacturing. Pertuzumab is an immunoglobulin G1 with a variable region against the human HER2 protein, a human-mouse monoclonal 2C4 heavy chain, disulfide bound with a human-mouse monoclonal 2C4 κ-chain. It is manufactured recombinantly in CHO cells.